Posted by Michael Wonder on 20 Nov 2015
CADTH calls for patient input on a new submission from GSK for mepolizumab
20 November 2015 - CADTH has received notice of a pending submission from GSK for mepolizumab for use by patients with severe, eosinophilic asthma.
For more details, go to: https://www.cadth.ca/mepolizumab
